Explore the options in chronic lymphocytic leukemia (CLL) with these downloadable slides from our CLL meeting series. Stay informed on the treatment and management of CLL in high-risk patients, those with comorbid conditions, and patients with potential contraindicated drugs.
Feb 14, 2018
Feb 14, 2019
Managing the Challenging Patient: A Focus on Patients With CLL
Anthony Mato, MD
This activity has been designed to meet the needs of medical oncologists and hematologist, nurses, physician assistants, nurse practitioners, and other healthcare professionals who treat or manage patients with CLL.
After successful completion of this educational activity, participants should be able to:
- Select optimal therapy based on patient and disease characteristics
- Identify proper sequence of therapeutic options for specific patients
- Compare side effect profiles of targeted therapies and select the most appropriate treatment based on patient and disease characteristics
This educational activity is supported by a grant from Gilead Sciences, Inc.
Enduring Materials From a Certified Activity
This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.
This activity is provided by prIME Oncology.
Disclosure of Relevant Financial Relationships
prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Mato has disclosed that he has received consulting fees from AbbVie; AstraZeneca; Celgene; Gilead Sciences, Inc.; Janssen; and Pharmacyclics. He has also disclosed membership on advisory committees or review panels for Gilead Sciences, Inc.; Pharmacyclics; and TG Therapeutics. He has agreed to disclose any unlabeled/unapproved uses of drugs referenced in his presentation.
The employees of prIME Oncology have disclosed:
- Janice Galleshaw, MD (medical director content reviewer/planner) – no relevant financial relationships
- Briana Betz, PhD (scientific content reviewer/planner) – no relevant financial relationships
- Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.